

Approval date: _	
Assigned to: _	
Budget: _	

WISH APPLICATION

Date of Request:	-		
WISH APPLICATION INFORMAT	ION:		
Name of wish child:		Sex:	Age:
Address/Apt. #:			
City/State/Zip:			
Date of birth:			
Parent(s)/Guardian(s):			
(Please	identify relationship to wish child for each	ch parent/guardian listed)	
Parent/Guardian Phone:	(Hom	e) Family Member:	
Parent/Guardian Phone:	(Worl	k/Cell) Family Member: _	
Email Address:			
Please list name, age, and birth da and reside in the home with the Ch	ild. Only family members res	iding in the immediate ho	busehold are eligible.
Name:	-		
Name:	-	•	
Name:	_		
Name:	-	•	
Name:	Age/DOB:	Relationship to child	d:
Name:	Age/DOB:	Relationship to child	d:
Has this Wish Child or any other ch Carolina Sunshine for Children or a	•	•	•
If yes, child's name:	Wish Organizati	on:	Date:

WISH INFORMATION:		
Requested Wish:		
Requested Wish dates:		
Why do you feel this child needs this	wish?	
•	e year following their approval. After that time a new Wish Application the Carolina Sunshine Board of Directors.	
THIS AREA FOR PHYSICIAN'S US		
is life-threatening at the time this	gned by the Attending Physician, confirming that the Child's illness Wish Application is submitted.	
Medical Diagnosis:		
Please include specific details on and Appendix A) and return as pa	the Physician's Statement of Wish Child Qualification form (page 4 or tof the Wish Application.	
Attending/Referring Physician:		
Office Address:		
Physician's Phone:	Physician's Fax:	
Physician's Signature:		
Wish Requested by:		
Address:		
City/State/Zip:		
Phone:	Email:	
As the person or organization request above information is complete, accura	ting a Wish from Carolina Sunshine for Children, Inc., I certify that the ate, and true.	
By:	Date:	

Carolina Sunshine for Children Publicity Release

I/We	D 44 140	
1Names of Parent(s)/G	, Parent(s)/Guard	dian(s) of
να του		
Name of Wish Child	and Name of Accompanying Brother(s) and/or	Sister(s)
2. AND/OR	, Parent(s)/0	Guardian(s) of
Name	es of Parent(s)/Guardian(s)	. ,
	Accompanying Child(ren)	
3. AND/OR		
	Accompanying Adult(s) 18 Years or Older	
	nat I/we have requested that I/we be allowed to by CAROLINA SUNSHINE FOR CHILDREN, IN	
consideration of CAROLINA SUN SUNSHINE FOR CHILDREN, INC	below, on my/our behalf and on behalf of the SHINE FOR CHILDREN, INC. granting said wis c. or any of its agents, directors, officers, servants interviews with me/us in such manner as they cho	h, I/we authorize CAROLINA or employees to photograph
in the taking of said photographs, in the future, all of said photogra	SUNSHINE FOR CHILDREN, INC. or any person films, and/or electronically recorded interviews to phs, films, and/or electronically recorded intervipapers, television and radio stations, and/or any tion or news to the general public.	distribute now or at any time ews to anyone including the
servants or employees to copy an	A SUNSHINE FOR CHILDREN, INC. or any of independent of the distribution of the distribution of the such that is a such that the such that is a such that it is a such that it is a such that it is a such that is a such that it is	om me/us to distribute now or
as to television and radio stations	SUNSHINE FOR CHILDREN, INC. to disclose s, newspapers or magazines, or any other form or name(s) and the details of the wish in which I a	of news or public media, now
I/We hereby promise that I/we have	ve read the foregoing Release and have execute	d it freely and voluntarily.
Witness	Parent/Guardian	Date
Witness	Parent/Guardian	Date
Witness	Accompanying Other Adult	Date
Witness	Accompanying Other Adult	 Date

Carolina Sunshine for Children Physician's Statement of Wish Child Qualification

basis) who present with a life-threatening condition at the time of wish referral. Wish Child's name: Please review the Definitions below and check any/all that apply for this child: 1. Progressive disorders – those that become more severe over time. __ 2. Degenerative disorders – characterized by a gradual deterioration of the body or mind that would lead to increased impairment or loss of function. ___ 3. Malignant – cancerous, tending to metastasize, threatening to life. Possible Qualifying Diagnoses that would be considered can be found in Appendix A (attached). Please review and document below the appropriate diagnosis/diagnoses below: The list in Appendix A is not all-inclusive. The Board of Directors of Carolina Sunshine for Children will review all requests for possible approval. Please list below any specific diagnoses and medical information to assist in our review process. I certify that this Wish child currently has a life-threatening condition and the above medical information is accurate to the best of my knowledge.

Purpose statement: To grant wishes to children ages 3 through 18 years (or 21 years on case-by-case

End of Wish Application

Physician's signature: _____ Date: _____

The information contained in this Wish Application is confidential.

Mail applications to: Carolina Sunshine for Children, Inc. P.O. Box 1803 ● Columbia, South Carolina, 29202

Page 4 of 10

Revised: 08/2024

Appendix A - Carolina Sunshine for Children List of Possible Qualifying Diagnoses

General Carolina Sunshine Wish Conditions:

- 1. Carolina Sunshine for Children grants wishes to children with serious or life-threatening illnesses.
- 2. The Child must be age 3-18 (up to 21 years old will be assessed on a case-by-case basis).
- 3. The Child must be a resident of South Carolina. A Child being treated at a medical facility outside of the state of South Carolina is still eligible.
- 4. The child must not have previously been a recipient of a Wish from Carolina Sunshine for Children or any other wish-granting organization.
- 5. Only one Wish will be granted per Child.
- 6. Only members of the immediate household and family may participate in the wish. This includes brothers, sisters, moms and dads. Contact a Carolina Sunshine for Children Board Member regarding Foster families.
- 7. The Wish must be the Wish of the Child.
- 8. Carolina Sunshine for Children does not grant wishes for children to receive motor vehicles, pools, or firearms.

There may be medical conditions not described below which can be considered on a case-by-case basis to determine if criteria is met for eligibility.

CARDIOLOGY

Complex congenital heart disease, such as: Single ventricle, Double inlet left ventricle, Tricuspid
atresia, Aortic atresia, Mitral atresia, Hypoplastic left heart syndrome, Pulmonary atresia, Shone's
complex
Congestive heart failure
Hypertrophic, restrictive, dilated, and/or arrhythmogenic right ventricular cardiomyopathy (ARVC)
Implanted cardiac defibrillator
Implanted ventricular assist device
Left ventricular heart failure
Long QT syndrome
Necessary frequent hospitalizations after repair of a congenital heart defect (routine studies requiring
hospitalization are not included)
Placement on the heart transplant list
Pulmonary arterial hypertension
Recipient of a heart or heart-lung transplant
Status post Fontan procedure
Tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals
Ventricular fibrillation
May be eligible with complicating comorbidities: Common arterial trunk, Complications from
immunosuppressive therapy, Double outlet right ventricle, Discordant ventriculoarterial connection,
Heart failure, Pacemaker implantation, Subaortic stenosis, Tetralogy of Fallot, Myocarditis with
significant sequelae

ENDC	CRINOLOGY
	Hyperinsulinism with persistent hypoglycemia after pancreatectomy or on Diazoxide
	Multiple endocrine neoplasia (MEN) syndromes with evidence of cancer
	Panhypopituitarism requiring hormone replacement with hydrocortisone and/or desmopressin
	Thyroid cancer (requiring chemotherapy infusions or radiation treatment and referred within one year of
	completion of the above mentioned treatment)
	X-linked adrenoleukodystrophy (all others will be reviewed on a case-by-case basis)
	X-linked hypophosphatemic rickets
	Congenital adrenal hyperplasia
META	BOLIC CONDITIONS
	Congenital defects in glycosylation
	Cystinosis
	Disorders of glycosaminoglycan metabolism, mucolipidosis, oligosaccharidoses
	Disorder of urea cycle metabolism
	Fabry (Anderson) disease
	Gaucher disease
	Glycogen storage disorders
	Krabbe disease
	Lesch-Nyhan syndrome
	Amino acidopathies, including but not limited to: Maple syrup urine disease, Tyrosinemia, Nonketotic
	hyperglycemia
	Menke disease
	Metachromatic leukodystrophy
	Mitochondrial/energy production defects
	Neurotransmitter defects
	Niemann-Pick disease
	Organic acidemias
	Peroxisomal disorder
	Prader-Willi syndrome with comorbidities
	Sphingolipidosis Tax On a language and a second sec
	Tay-Sachs disease
Ш	Wilson disease
GAST	ROENTEROLOGY
	Bowel/intestinal transplant
	Chronic progressive liver disease with decompensation
	Hepatopulmonary syndrome
	Irritable Bowel Disease resulting in short gut disease with prolonged parental support or complications resulting from immunosuppressive therapy or surgery
	Chronic liver failure or end-stage liver disease
	Liver transplant
	Malignancy or inherited premalignant conditions
	Portal hypertension
	Short bowel syndrome or intestinal failure requiring prolonged TPN support
	Status post liver transplant (with on-going life-threatening complications)
	May be eligible with complicating comorbidities: Atresia of the bile ducts, Complications from

immunosuppressive therapy, Crohn's disease, Hirschsprung's disease, Pancreatitis, Ulcerative colitis

GENE	GENETICS			
	Congenital anomalies, chromosome abnormalities, or other genetic conditions with associated life-			
	threatening complications such as: Intractable seizures, Structural upper airway and abnormalities or			
	chronic pulmonary symptoms, Heart anomalies meeting cardiology guidance, Chronic renal failure,			
	Associated major gastrointestinal dysfunctions, Childhood-onset neurodegenerative symptoms			
	Chromosome abnormalities: Trisomy 13, Trisomy 18			
	Neurodegenerative disorders: Neuronal ceroid lipofuscinosis (Batten disease), adrenoleukodystrophy,			
_	metachromatic leukodystrophy, San Filippo syndrome			
	Muscular dystrophies with potential childhood onset life-threatening pulmonary or cardiac			
_	complications: Congenital myotonic dystrophy, Duchenne muscular dystrophy			
	Metabolic disorder, or inborn error of metabolism, with life-threatening metabolic crises resulting in			
_	progressive developmental regression			
	Skeletal dysplasias with chronic or degenerative pulmonary or multi-organ system complications:			
	Jeune, Rhizomelic chondrodysplasia punctata type 1			
	Other genetic conditions with child-hood onset progressive neurodevelopmental and/or multi-organ			
	system involvement: Barth syndrome, Rett syndrome, severe forms of mucopolysaccharidoses (MPS			
	disorders) and mucolipidosis (ML) disorders			
	()			
HEMA	TOLOGY			
	Aplastic anemia and other bone marrow failure syndromes			
	Bone marrow transplant (within one year)			
	Hemophagocytic lymphohistiocytosis			
	Severe congenital or acquired bleeding disorders with: Hemorrhage in vital organs resulting in			
	significant morbidity (e.g. intracranial hemorrhage with neuro deficits, organ injury requiring intensive			
	supportive care, etc.)			
	Severe combined immunodeficiency (SCID)			
	Stem cell transplant (within one year)			
	Severe congenital or acquired blood cell disorders with: Treatment requiring chemotherapy infusions,			
	Serious complications resulting from transfusion therapy (e.g. iron overload)			
	Sickle cell disease (Hb-SS, Hb-SC) or thalassemia with severe or chronic complications such as: Acute			
	chest syndrome, Splenic sequestration, Stroke or severe cerebrovascular disease, Necessary regular			
	transfusion, Pulmonary hypertension, Multiple severe pain crises within past year, End organ damage			
	requiring additional supportive measures			
	May be eligible with complicating comorbidities: Complications of immunodeficiency or from			
	immunosuppressive therapy, Coagulation disorders			
_	NOLOGY Rena magnety transplant (within and year of transplant)			
	Bone marrow transplant (within one year of transplant)			
	Immunodeficiencies with severe autoimmune complications and/or significantly diminished life			
	expectancy Primary immunodeficioneiros requiring lifelong treetment: Life expectancy is enticipated to be			
	Primary immunodeficiencies requiring lifelong treatment: Life expectancy is anticipated to be			
	significantly shortened if the treatment is not available, E.g. Wiskott-Aldrich, Bruton's			
	agammaglobulinemia, chronic granulomatous disease			
	Primary immunodeficiency diseases resulting in frequent unplanned hospitalizations where infection is			
	not well controlled			
	Severe combined immunodeficiency disease (SCID)			
	Status bone marrow transplant (with ongoing life-threatening complications)			
	May be eligible with complicating comorbidities:			
	Complications from immunosuppressive therapy			

INFE	CTIOUS DISEASE HIV
	Congenital/Neonatal infections with sequelae, including but not limited to: CMV, Toxoplasmosis, HSV
	Infections with neurologic sequelae, including but not limited to: GBS meningitis with resultant
	developmental delay, S. pneumo meningitis with resultant deafness
INTEN	NSIVE CARE
	Febrile Infection-Related Epilepsy Syndrome (FIRES)
	Hemophagocytic lymphohistiocytosis (HLH)
	Hypoxic brain injury
NEPH	IROLOGY
	Chronic Kidney disease, stage 3 with multiple acute illnesses/exacerbations in the last year requiring hospitalization
	Chronic Kidney disease, stage 4 or higher
	Dialysis dependent renal disease
	Kidney transplant (within one year of transplant)
	Kidney diseases dependent on long-term infusions and/or plasma exchange (e.g. atypical hemolytic uremic syndrome requiring chronic anti-complement therapy to stay in remission)
	Status post kidney transplant (with ongoing life-threatening complications)
	May be eligible with complicating comorbidities: Refractory nephrotic syndrome (e.g. multiple acute
	illnesses or relapses requiring infusion or medication and multiple immunosuppressive medications), Complications from immunosuppressive therapy
NEUR	ROLOGY/NEUROSURGERY
	Neurodegenerative disease with significantly shortened life expectancy including: Leukodystrophy,
	Alpers disease, Leigh syndrome, Rett syndrome, Pelizeus Mertzbacher Syndrome, Neuronal brain iror accumulation (NBIA), Friedreich's ataxia
	Congenital neuromuscular disease with respiratory or cardiac complications including: Duchenne
	muscular dystrophy, Spinal muscular atrophy types 1 and 2, Myotonic Dystrophy
	Epilepsy/uncontrolled seizures that are: Intractable, Refractory, Treatment-resistant, Includes Lennox-
	Gastaut Syndrome
	Progressive cerebrovascular disease (e.g., stroke) with ongoing life-threatening complications: Moya
	Moya Disease, MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes),
	Osler-Weber-Rendu Syndrome, Fabry's Disease, CADASIL/CARASIL (cerebral autosomal
	dominant/recessive arteriopathy with subcortical infarcts and leukoencephalopathy), Sickle Cell
	Disease with Stroke
	Dysautonomia Conditions: Familial dysautonomia (Riley-Day), Traumatic Brain Injury with PAID
	(Paroxysmal Autonomic Instability with Dystonia), Cerebral Palsy with PAID, Spinal Cord Injury with Autonomic Dysreflexia
	Cerebral palsy with associated life-threatening complications e.g., intractable seizures, compromised
	respiratory failure.
	Profound neurodevelopmental delay with associated life-threatening comorbidities requiring significant
	and ongoing life-sustaining medical support.
	Traumatic brain or spinal cord injury with associated life-threatening comorbidities requiring significant
	and ongoing life-sustaining medical support.
	Traumatic brain or spinal cord injury with life-threatening complications, e.g. intractable seizures,
	compromised respiratory failure.
	Tuberous sclerosis, involving the brain or spinal cord

	Megalencephaly, Myopathy, Neurofibromatosis, Spina bifida, Huntington's disease
ONCO	LOGY
П	Bone marrow/stem cell transplant (within one year of transplant)
	Low grade tumors with any of the following criteria: Requiring chemotherapy infusions or radiation
	treatment and referred within one year of completion of the above mentioned treatment, Requiring more
	than one major surgery, such as a craniotomy, Location of tumor requiring ongoing medical intervention
	(e.g. seizures or endocrine deficit, significant functional impairment such as paralysis, or other major
	neurologic impairment), Associated with extensive complications (e.g. a lengthy unplanned hospital
	stay)
	Malignant neoplasm and neoplasm of unspecified/uncertain behavior requiring and referred within one
_	year of completion of chemotherapy infusions or radiation treatment
	Status post bone marrow/stem cell transplant with ongoing life-threatening complications
	May be eligible with complicating comorbidities: Complications from immunosuppressive therapy
_	ONARY
	Chronic hypoxemia requiring supplemental oxygen
	Chronic respiratory failure
	Chronic ventilator dependence
	Cystic fibrosis
	Lung transplant
	Moderate to severe lung disease secondary to chemotherapy and radiation
	Placement on the lung transplant list
	Progressive histiocytosis, including multifocal
	Progressive interstitial lung disease associated with immunodeficiency, autoimmune disease, or
	immune dysregulation
	Pulmonary fibrosis
	Pulmonary graft versus host disease
	Pulmonary hypertension
	Pulmonary lymphangiectasia
	Severe respiratory compromise incompletely responsive to therapy and resulting in recurrent life-
	threatening episodes
	Surfactant protein dysfunction
	Tracheostomy placement for chronic respiratory failure or severe airway obstruction
	May be eligible with complicating comorbidities: Acute respiratory failure, Bronchopulmonary dysplasia,
	Tracheostomy with oxygen requirements (depending on underlying medical diagnosis or reason for tracheostomy), Chronic obstructive pulmonary disease, Primary ciliary dyskinesia, Severe asthma,
	Severe restrictive lung disease, Complications from immunosuppressive therapy
RHEU	MATOLOGY
	Antiphospholipid syndrome with recurrent thrombosis/active disease (not just positive antibody titers)
	Autoinflammatory conditions (e.g. TRAPS, CINCA/NOMID, HIDS, CANDLE, DIRA)
	Chronic vasculitis: Eosinophilic granulomatosis with polyangiitis, Granulomatosis, Microscopic
_	polyangiitis, Polyangiitis, Polyarteritis nodosa, Takayasu arteritis
	Juvenile dermatomyositis with any end-organ involvement, calcinosis, or otherwise recalcitrant (greater
_	than one year of treatment or two or more relapses)
	Mixed connective tissue disease with end-organ involvement
	Pediatric systemic lupus erythematous with end-organ involvement

May be eligible with complicating comorbidities: Arhinencephaly, Encephalopathy, Hydrocephalus,

Polychondritis resulting in end-organ damage
Progressive Systemic Sclerosis (Systemic Scleroderma)
Systemic JRA/JIA with macrophage activation syndrome (MAS) referred within 12 months of MAS
episode of having continuing MAS issues
May be eligible with complicating comorbidities: Complications from immunosuppressive therapy

Page 10 of 10 Revised: 08/2024